Abstract:11534 Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Radical resection is the standard treatment of localized GIST, yet the 5-year recurrence rate for high-risk GIST is more than 50%. It remains unclear whether detecting post-surgery molecular residual disease (MRD) via circulating tumor DNA (ctDNA) can predict the recurrence of high-risk locally advanced GIST. Methods: Patients with high-risk stage II-III GIST who underwent R0 surgery and following adjuvant imatinib/avapritinib were enrolled prospectively. Surgical tissue samples were collected. Blood samples were drawn pre-surgically, and at 7 days, 1 month, and every 3–6 months post-surgically. Tumor-derived variants were identified by whole-exon sequencing of the surgical tissues. Up to 50 highly ranked variants with a variant allele frequency 3.0% were selected for the personalized panel design, which was subsequently used to assess MRD status. Results: A total of 36 patients with a median age of 65 years were included in the current analysis (data cutoff on January 16, 2024). Most tumors (17/36, 47%) were located at the stomach or gastroesophageal junction, and 94.4% of patients (34/36) did not receive neoadjuvant treatment. The mean maximum diameter of tumors was 7.87 ± 2.87 cm. At present, 36 tissue samples, 34 pre- and 161 post-surgical blood samples were collected and analyzed. Tissue sample-based sequencing identified variants in KIT and PDGFRA in 31 (86%) and 4 (11%) patients, respectively. 98.4% (1003/1019) of tumor variants included in personalized panels were patient-specific. ctDNA was detected in 64.7% (22/34) of pre-surgical plasma samples. The ctDNA-positive rate at baseline was associated with tumor mutation burden (p < 0.05), rather than tumor size (p = 0.6). Landmark analysis at 1 week post-surgery showed that 12.1% of patients were positive for ctDNA. Up to now, 4 patients were identified with tumor recurrence based on imaging results. Among these patients, 3 patients (3/4) exhibited ctDNA positivity preceding radiological recurrence. Notably, a 71-year-old patient was ctDNA-positive at 1 week post-surgery. Longitudinal analysis revealed that his ctDNA became negative after adjuvant treatment but turned positive at 9 months post-surgery, with a lead time of 2 months prior to his radiological recurrence. Additionally, a patient tested positive for ctDNA at 3 months post-surgery but had negative imaging results. Follow-up visits are ongoing for this patient. Conclusions: The present study suggests that personalized tumor-informed ctDNA has the potential to inform recurrence in high-risk stage II-III GIST patients. Clinical enrollment is still ongoing.

Association Between Risk of Recurrence Assessment and Adjuvant Treatment (tx) Duration in Patients (pts) with Resected Gastrointestinal Stromal Tumors (Gists)

Surgical Management and Outcomes of Duodenal Gastrointestinal Stromal Tumors.

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection

Risk of Disease Recurrence and Mortality in Gastrointestinal Stromal Tumor (gist) Patients Receiving Short-Term Versus Long-Term Imatinib Adjuvant Therapy: A Chart Review Analysis.

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Investigation Of Gastrointestinal Stromal Tumor (Gist) Care Management In Gist Patients (Pts) Receiving Short-Term Versus Long-Term Imatinib (Im) Adjuvant Therapy: A Chart Review Analysis.

Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib As Adjuvant Therapy—A Retrospective Chart Extract-Based Approach

Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding As Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors.

Mutational Characteristics of Gastrointestinal Stromal Tumors: A Single-Center Analysis of 302 Patients

Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients—a Chart Extract-Based Approach

Prescribing Decision Drivers in Patients with Recurrent Gastrointestinal Stromal Tumor (GIST) Previously Treated with Adjuvant Imatinib: A Retrospective Chart Extract-Based Approach.

Postoperative Imatinib in Patients with Intermediate Risk Gastrointestinal Stromal Tumor

Is 3-Years Duration of Adjuvant Imatinib Mesylate Treatment Sufficient for Patients with High-Risk Gastrointestinal Stromal Tumor? A Study Based on Long-Term Follow-Up

[Efficacy Observation on Imatinib Adjuvant Therapy with Longer Duration in Patients with Gastrointestinal Stromal at Intermediate or High Risk of Recurrence].

Impact of Kit and Pdgfra Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors after Complete Primary Tumor Resection

Personalized Tumor-Informed Circulating Tumor DNA Analysis in Monitoring Recurrence Following Resection of High-Risk Stage II-III Gastrointestinal Stromal Tumor.

Characteristics of Gastrointestinal Stromal Tumor (GIST) Patients Receiving Short-Term Versus Long-Term Imatinib (IM) Adjuvant Therapy: A Chart Review Analysis.